Introduction
============

Recent studies investigating chronic pituitary dysfunction resulting from TBI have reported a prevalence of posttraumatic hypopituitarism (PTHP) ranging from 5 to 95% with a median of 35%, the variation being primarily due to differences in screening criteria (Bavisetty et al., [@B8]; Srinivasan et al., [@B85]; Berg et al., [@B11]; Englander et al., [@B29]; High et al., [@B41]; Kokshoorn et al., [@B53], [@B52]; Krahulik et al., [@B54]; Park et al., [@B70]; Pavlovic et al., [@B71]; Reimunde et al., [@B78]; Schneider et al., [@B80]). Pituitary hormone disorders are frequently among the immediate consequences of TBI; some resolve during the following months while a smaller proportion of new dysfunctions emerge (Agha et al., [@B3]; Aimaretti et al., [@B6]; Schneider et al., [@B81], [@B80]; Tanriverdi et al., [@B92], [@B94]; Klose et al., [@B51]; Krahulik et al., [@B54]). By ∼6 months subsequent to TBI, the pattern of pituitary deficits is considered to be relatively permanent.

The risk factors and the mechanisms, other than immediate trauma-induced tissue damage and subsequent edema, for chronic hypothalamo-pituitary dysfunction due to TBI are unclear. Roles for polymorphisms in apolipoprotein E genotype (*APOE*), inflammatory processes -- both systemic and neural, and anti-hypothalamic (AHAs) and anti-pituitary antibodies (APAs) have been proposed, and each has empirical support.

There is evidence that the apolipoprotein E (*APOE*) ε3/ε3 genotype may be associated with a reduced risk of TBI-related hypopituitarism. *APOE* ε3 is the most common of the three alleles and is found in more than half of the general population. The ε2 and ε4 alleles have been associated with altered risks for Alzheimer's disease, hyperlipoproteinemia, and atherosclerosis. Pituitary dysfunction in patients with TBI has been found to be significantly less prevalent in individuals with the *APOE* ε3/ε3 genotype (17.7%) than in patients with other genotypes (41.9%; *p* = 0.01; Tanriverdi et al., [@B93]).

Evidence for the involvement of APAs and/or AHAs in the development of chronic PTHP comes from two studies. APAs were detected in 44.8% of patients who had completed a 3-year-follow-up after TBI and in none of the healthy control subjects, and the prevalence of hypopituitarism was significantly higher in APA-positive (46.2%) than APA-negative TBI patients (12.5%; *p* = 0.04; Tanriverdi et al., [@B94]). In another study of active and retired boxers, AHAs were detected in 21.3% and APAs in 22.9% of boxers, whereas no evidence of APAs or AHAs was found in control subjects (Tanriverdi et al., [@B97]).

It is well established that TBI results in the acute induction of both neural and systemic inflammatory responses and consequent anti-inflammatory counter-responses (Lu et al., [@B58]; Ziebell and Morganti-Kossmann, [@B107]). In addition, animal studies provide evidence of the development of a chronic inflammatory state after TBI. Three months after moderate focal brain injury in rats, persistent major histocompatibility complex (MHC)-II up-regulation, mononuclear phagocytosis, and elevated interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) synthesis were observed in large areas of the ipsilateral hemisphere (Holmin and Mathiesen, [@B43]). In another study, 2 months after cortical contusion injury to the medial frontal cortex of rats, IL-1β was significantly increased in the cortex and hypothalamus compared with a sham--trauma group, and glial fibrillary acidic protein (GFAP) was elevated in the cortex, hypothalamus, and anterior pituitary of the TBI group (Kasturi and Stein, [@B47]).

In general, the frequency of occurrence of pituitary hormone abnormalities has not been found to be related to the severity of the trauma (Lieberman et al., [@B57]; Agha et al., [@B1]; Aimaretti et al., [@B5], [@B6]; Bondanelli et al., [@B13]; Schneider et al., [@B81]; Park et al., [@B70]; Kokshoorn et al., [@B52]), although there have been reports of a positive relationship (Kelly et al., [@B49]; Klose et al., [@B51]). Of the traumatic brain injuries sustained by ∼1.7 million Americans annually (Faul et al., [@B31]), 75% are considered mild TBI (mTBI; National Center for Injury Prevention and Control, [@B69]).

Mild TBI is defined by the American Congress of Rehabilitation Medicine (ACRM) as a head trauma resulting in any one of the following: loss of consciousness (LOC) for 30 min or less, alteration of mental state for up to 24 h (being dazed, confused, disoriented, etc.), or loss of memory for events immediately before or after the trauma (American Congress of Rehabilitation Medicine, [@B7]). The terms mTBI and concussion are frequently used interchangeably (National Center for Injury Prevention and Control, [@B69]; Department of Veterans Affairs/Department of Defense, [@B26]).

Mild TBI-related chronic pituitary dysfunction has been reported in boxers and kick boxers subjected to repetitive head injuries. In a preliminary study, 45% of professional boxers were found with apparent growth hormone deficiency (GHD), but no other pituitary hormone deficiencies were observed (Kelestimur et al., [@B48]). In a larger study of active and retired boxers 18% had pituitary hormone deficiencies in one or more axes (Tanriverdi et al., [@B95]). An investigation of pituitary dysfunction in amateur kick boxers revealed GH and/or adrenocorticotropin (ACTH) deficiencies in 27.3% of the athletes (Tanriverdi et al., [@B96]).

In 2010, the injuries in 80% of over 30,000 U.S. military service members medically diagnosed with TBI were classified as mTBI (Military Health System, [@B66]), and mTBI sustained from explosive blasts is one of the most common combat injuries resulting from deployment to Iraq or Afghanistan. About 10--20% of returnees report having experienced at least one blast concussion (Tanielian et al., [@B90]; Terrio et al., [@B99]).

The extensive documentation of the high prevalence of hypopituitarism after TBI from all causes and the absence of any published studies of the frequency of PTHP after blast-related mTBI provided the rationale for this investigation of hypopituitarism in U.S. Veterans of combat in Iraq and/or Afghanistan who have experienced at least one blast concussion.

Materials and Methods
=====================

Participants and sample acquisition
-----------------------------------

The VA Puget Sound Health Care System (VAPSHCS) Institutional Review Board and the U.S. Army Medical Research and Materiel Command (USAMRMC) Office of Research Protections (ORP) Human Research Protection Office (HRPO) approved the subject protocol with a waiver of informed consent. All plasma and serum samples, demographic, and blast exposure data were obtained from an established biorepository entitled "Alzheimer's Disease Research Center (ADRC) Participant Registry and Sample Repository." All subjects whose samples were utilized had consented to have their samples and data used in future research of this type.

The mTBI Veteran participants (T group) whose samples were obtained from the repository were a convenience sample of 26 male Veterans recruited from VAPSHCS, all of whom had documented hazardous duty experience in Iraq and/or Afghanistan with the U.S. Armed Forces and had reported experiencing at least one blast exposure in the war zone that resulted in acute mTBI as defined by ACRM criteria (American Congress of Rehabilitation Medicine, [@B7]) except that Glasgow Coma Scale scores were not obtained in the combat setting. Samples from the repository were also collected from seven male Veterans who had been deployed to Iraq and/or Afghanistan but who had not been exposed to blast and had no history of TBI. These individuals made up the deployment control (DC) group.

Additional samples from the repository which were used to establish normal hormonal reference ranges had been collected from 59 cognitively normal male community volunteers recruited from the ADRC, all of whom were medically healthy and had Mini-Mental State Examination scores of 29.4 ± 1.0 (mean ± SEM; range 27--30); Clinical Dementia Rating scores of zero; no evidence or history of cognitive or functional decline; and no history of blast exposure or head injury. These samples were used only for the establishment of normative hormone concentrations with our assay methods. Resting blood samples had been collected from all participants between 9:00 and 10:00 a.m., at least 30 min after the insertion of an intravenous catheter in an antecubital vein.

None of the Veteran or community control participants had a history of blast exposure, head injury with LOC greater than 30 min; penetrating head wound; seizure disorder; insulin-dependent diabetes; current or past DSM-IV diagnoses of schizophrenia, other psychotic disorders, bipolar disorder, or dementia; or a DSM-IV diagnosis of alcohol or other substance abuse or dependence within the previous 3 months. Participants using medications likely to affect brain function, such as opioids, benzodiazepines, or anti-depressants, were asked not to take those medications for 24 h prior to blood sampling.

Blast exposure assessment
-------------------------

Blast exposure and mTBI histories had been obtained from mTBI Veteran participants during a clinical interview in which specific inquiries were made regarding total number of blast exposures accompanied by acute symptoms of TBI and/or LOC in Iraq and/or Afghanistan and lifetime history of non-blast exposure head injuries accompanied by acute symptoms of TBI and/or LOC (e.g., sports or motor vehicle accident-related concussion).

Neurological assessment
-----------------------

All subjects underwent a full neurological examination, including the Unified Parkinson's Disease Rating Scale (UPDRS) motor section (Martínez-Martín et al., [@B61]). Olfactory function was assessed using the Brief Smell Identification Test (B-SIT; Doty et al., [@B27]).

Hormone measurement
-------------------

Blood samples for the measurement of plasma hormone concentrations were collected between 9:00 and 10:00 a.m. in chilled tubes containing ethylenediaminetetraacetic acid (EDTA), placed on ice, and centrifuged at 4°C prior to removal of the plasma fraction. Blood samples for measurement of serum hormones were collected in serum-separator tubes, allowed to clot at room temperature for 10 min, and centrifuged to isolate serum. Serum and plasma samples were aliquoted and stored at −70°C. Twelve pituitary or target-organ hormones were measured in these samples. The type, source, and performance characteristics of the assay kits used for the measurement of hormone concentrations in serum and plasma are shown in Table [1](#T1){ref-type="table"}. ACTH, cortisol, thyroid-stimulating hormone (TSH), oxytocin, and vasopressin concentrations were determined in plasma; free thyroxine, luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone, insulin-like growth factor-I (IGF-I), growth hormone, and prolactin were measured in serum.

###### 

**Sources and characteristics of hormone assay kits**.

  Assay          Kit name                                      Manufacturer              Location
  -------------- --------------------------------------------- ------------------------- ----------------------
  ACTH           ACTH Immunoradiometric (IRMA) Assay           Scantibodies Laboratory   Santee, CA, USA
  Cortisol       GammaCoat™ Cortisol ^125^I RIA                Diasorin                  Stillwater, MN, USA
  FSH            DELPHIA hFSH                                  Perkin Elmer              Waltham, MA, USA
  GH             hGH-ELISA, Ultra-Sensitive                    DSL                       Webster, TX, USA
  IGF-I          IGF-I RIA                                     IBL America               Minneapolis, MN, USA
  LH             ImmuChem™ Coated Tube LH ^125^I RIA           MP Biomedicals            Costa Mesa, CA, USA
  Oxytocin       Oxytocin EIA Kit -- Extraction-free           Peninsula Labs/Bachem     San Carlos, CA, USA
  Prolactin      ImmuChem™ Coated Tube Prolactin ^125^I IRMA   MP Biomedicals            Costa Mesa, CA, USA
  Testosterone   Total Testosterone                            Siemens Diagnostics       Los Angeles, CA, USA
  Thyroxine      Free Thyroxine (FT~4~) Microplate EIA         MP Biomedicals            Costa Mesa, CA, USA
  TSH            ImmuChem™ Coated Tube TSH ^125^I IRMA         MP Biomedicals            Costa Mesa, CA, USA
  Vasopressin    Vasopressin Direct RIA                        ALPCO                     Salem, NH, USA

  Hormones       Assay type          Sample type   Assay size   Sample size   Assay range        Sensitivity   Intra-assay CV   Inter-assay CV
  -------------- ------------------- ------------- ------------ ------------- ------------------ ------------- ---------------- ----------------
  ACTH           IRMA                Plasma        100 Tubes    200 μl        9--1693 pg/ml      \<1.0 pg/ml   4.05             6.66
  Cortisol       RIA                 Plasma        100 Tubes    10 μl         1--60 μg/dl        0.21 μg/dl    7.03             9.20
  FSH            Fluoroimmunoassay   Serum         96 Wells     25 μl         0.98--256 U/l      0.05 U/l      2.33             1.87
  GH             EIA                 Serum         96 Wells     100 μl        4.5--500 pg/ml     0.66 pg/ml    6.00             5.40
  IGF-1          RIA                 Serum         100 Tubes    100 μl        0.16--10.0 ng/ml   0.02 ng/ml    2.97             10.30
  LH             RIA                 Serum         100 Tubes    100 μl        2.5--200 mIU/ml    1.5 mIU/ml    5.90             7.90
  Oxytocin       EIA                 Plasma        96 Wells     50 μl         0--630 pg/ml       6.5 pg/ml     9.36             13.67
  Prolactin      IRMA                Serum         100 Tubes    25 μl         2.5--100 ng/ml     2.5 ng/ml     5.13             8.08
  Testosterone   Solid-phase RIA     Serum         100 Tubes    50 μl         20--1600 ng/dl     4 ng/dl       3.40             7.90
  Thyroxine      EIA                 Serum         96 Wells     50 μl         0.45--7.6 ng/dl    0.05 ng/dl    6.83             6.47
  TSH            IRMA                Plasma        100 Tubes    200 μl        0.2--50 μIU/ml     0.04 μIU/ml   4.10             5.23
  Vasopressin    RIA                 Plasma        100 Tubes    400 μl        1.25--80 pg/ml     0.1 pg/ml     6.00             9.90

Clinical lab data
-----------------

Measurements of plasma and urine osmolality were not available but urine specific gravity was measured and used as a criterion to determine functional vasopressin insufficiency.

Statistical analysis and criteria for pituitary deficiencies
------------------------------------------------------------

The criteria for PTHP, derived using hormone measurements from the 59 community control participants are shown in Table [2](#T2){ref-type="table"}. For each hormone, age-adjusted percentiles based on the lognormal distribution from community control participants were estimated and dysfunction in each of seven hormonal axes was defined (R Development Core Team, [@B76]). Hypopituitarism was defined as a dysfunction in at least one of these seven axes. These criteria were modeled after those used in published studies of hypopituitarism after TBI from all causes.

###### 

**Screening criteria for identifying abnormal circulating hormone levels**.

  Axis                      Criteria using lognormal distribution of community control reference sample
  ------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Adrenal insufficiency     Cortisol \< 10th percentile (6.7 μg/dl), and ACTH \< 10th percentile (18 pg/ml)
  Thyroid deficiency        Free T-4 \< 5th percentile (0.87 ng/dl), and TSH \< 50th percentile (2.39 μIU/ml)
  Hypogonadism              Total testosterone \< 5th percentile (330 ng/dl) and either LH or FSH \< 10th percentile (2.3 mIU/ml, 1.3 U/l, respectively) OR (total testosterone \< 5th percentile and prolactin \> 95th percentile (32 ng/ml)
  Vasopressin abnormality   Vasopressin \> 95th percentile (9.46 pg/ml) OR vasopressin \< 5th percentile (0.27 pg/ml) and urine specific gravity \< 1.003
  Prolactin abnormality     Prolactin \> 95th percentile (32.0 ng/ml) OR prolactin \< 5th percentile (6.7 ng/ml)
  GH deficiency             IGF-1 \< age-adjusted 10th percentile (SDS \< −1.4)
  Oxytocin deficiency       Oxytocin \< 5th percentile (22.7 pg/ml)
  Hypopituitarism           Abnormalities in at least one of these 7 axes

Results
=======

Plasma/serum hormone screening evaluations
------------------------------------------

Eleven of 26 mTBI subjects (T), or 42%, were found to have abnormal hormone values in at least one axis. As reported in earlier studies of PTHP, deficiencies in the growth hormone-IGF-I and pituitary--gonadal axes were observed most frequently (Bavisetty et al., [@B8]; Dusick et al., [@B28]; Schneider et al., [@B83]; Englander et al., [@B29]; Kokshoorn et al., [@B53]; Krahulik et al., [@B54]; Park et al., [@B70]; Pavlovic et al., [@B71]; van der Eerden et al., [@B103]).

Markedly low IGF-I levels are strong indicators of adult GHD (Juul et al., [@B46]; Hartman et al., [@B39]; Hadjadj et al., [@B38]; Ho, [@B42]; Prodam et al., [@B74]; Tanriverdi et al., [@B91]; Zgaljardic et al., [@B106]). The red line in Figure [1](#F1){ref-type="fig"} represents the cutoff level used to define our criterion for subnormal IGF-I levels indicative of probable GHD. The cutoff level was defined to be an IGF-I concentration below the age-adjusted 10th percentile level \[equivalent to an SD score (SDS) below −1.4\] of the community control reference sample (Figure [1](#F1){ref-type="fig"}; Table [2](#T2){ref-type="table"}). Five Veteran participants with mTBI (T-4, T-8, T-16, T-25, and T-28) were found to have serum IGF-I concentrations below this cutoff line. None of the Veteran participants in the DC group were found to have subnormal age-adjusted IGF-I levels (Figure [1](#F1){ref-type="fig"}).

![**IGF-I concentrations in serum from deployment control (DC) participants (triangles) and participants with mTBI (T, circles)**. The screening criterion for growth hormone deficiency was an IGF-I level below the age-adjusted 10th percentile of IGF-I concentration (diagonal red line) in the community control reference group. Serum IGF-I values of five Veterans with mTBI fell below this cutoff line. None of the DC group met this criterion.](fneur-03-00011-g001){#F1}

Three participants with mTBI (T-4, T-13, and T-28) were found with abnormal hormonal profiles indicating probable hypogonadism. The criteria were a total testosterone concentration less than the 5th percentile of the reference sample together with an LH or FSH level below the 10th percentile reference level (Figure [2](#F2){ref-type="fig"}; Table [2](#T2){ref-type="table"}). T-4 and T-28 also had the lowest two IGF-I levels among the participants (T-4: 126 ng/ml, SDS = −2.325; T-28: 86 ng/ml, SDS = −2.989). Elevated prolactin levels in conjunction with low testosterone are also indicative of hypogonadism. A serum prolactin concentration markedly higher than the 95th percentile of the reference sample was found in serum from participant T-4. A subnormal prolactin concentration (\<5th percentile), also associated with sexual dysfunction, was measured in serum from T-13.

![**Serum LH (left) and testosterone (right) in the deployment control (DC, triangles) and mTBI (T, circles) groups**. Screening criteria for hypogonadism: LH (or FSH) levels below the 10th percentile of the control range together with testosterone below the 5th percentile (red lines). Green circles mark data from 3 T subjects falling below both cutoffs. No DC subjects met both criteria.](fneur-03-00011-g002){#F2}

None of the Veterans in the DC group were found to have hormone levels indicative of hypogonadism. One participant in the DC group was found with a total testosterone concentration below the 5th percentile reference standard and another had an LH concentration below the 10th LH percentile, but neither exhibited the combined gonadotropin and testosterone deficiencies consistent with hypogonadism.

None of the Veteran participants in either the T or DC group exhibited abnormalities in the hypothalamic-pituitary--adrenocortical or hypothalamic-pituitary--thyroid axis (Table [3](#T3){ref-type="table"}). The corticotrophs and thyrotrophs are located in the protected median wedge of the anterior pituitary and are anatomically less vulnerable to injury than gonadotropin- and GH-secreting cells. This differential anatomical vulnerability correlates well with the frequency of chronic hormonal abnormalities observed after TBI (Bavisetty et al., [@B8]; Blair, [@B12]; Krahulik et al., [@B54]).

###### 

**Plasma or serum hormone concentration for each participant**.

  Subject    Age   \#BE   ACTH (pg/ml)   Cort (μg/dl)   LH (mIU/ml)   FSH (U/l)   tTest (ng/dl)   PRL (ng/ml)   TSH (μIU/ml)   fT-4 (ng/dl)   IGF-I (ng/ml)   GH (pg/ml)   AVP (pg/ml)   OT (pg/ml)
  ---------- ----- ------ -------------- -------------- ------------- ----------- --------------- ------------- -------------- -------------- --------------- ------------ ------------- ------------
  T-1        24    11     24             6.6            2.58          0.46        473             12.5          1.70           1.29           190             58           3.4           64
  **T-2**    26    6      20             11.9           2.03          --          669             9.6           1.92           1.67           185             71           **12.3**      181
  T-3        27    10     22             10.2           5.15          2.05        557             13.0          1.59           1.59           164             50           4.0           166
  **T-4**    33    15     19             7.5            **2.03**      2.06        **252**         **54.9**      1.17           1.22           **110**         11           8.0           88
  T-5        38    102    24             12.8           2.11          2.33        362             14.9          1.16           1.18           133             0            0.4           71
  T-6        46    5      29             12.1           1.95          1.41        402             11.1          1.08           1.09           143             152          0.7           61
  T-7        26    20     28             14.1           3.34          1.63        559             12.0          2.26           1.29           172             223          0.0           39
  **T-8**    25    21     35             11.3           2.72          4.02        401             11.9          1.13           1.55           **141**         294          0.2           44
  T-9        24    102    39             12.0           4.81          3.28        730             14.4          1.16           1.05           251             1288         8.0           52
  **T-10**   26    20     30             9.6            1.97          2.43        520             12.3          2.41           1.39           230             68           **0.2**       **22**
  T-11       28    9      31             10.2           1.64          2.38        382             9.2           1.30           1.22           182             0            1.1           36
  **T-12**   27    15     27             9.9            7.27          5.70        715             13.0          1.57           1.38           198             60           **12.0**      55
  **T-13**   31    7      40             7.8            **1.92**      **1.18**    **253**         **6.3**       2.24           1.14           187             0            6.4           50
  **T-14**   30    6      36             8.8            2.66          2.51        390             12.0          3.75           1.13           151             310          0.5           **19**
  T-15       27    11     16             7.4            2.27          3.56        377             10.1          1.40           1.14           168             42           4.4           85
  **T-16**   28    66     25             11.7           2.64          4.01        380             21.5          0.65           1.52           **126**         0            0.9           190
  T-17       25    18     26             11.2           9.32          3.00        465             17.1          1.26           1.25           197             0            4.8           151
  T-18       24    7      30             14.2           3.65          2.21        556             12.2          1.27           1.30           179             60           4.3           32
  T-19       30    1      32             18.6           5.44          3.01        457             11.7          1.55           1.13           190             66           0.0           46
  T-20       28    3      17             25.0           6.65          3.91        309             10.4          0.79           1.31           210             1696         7.9           519
  **T-22**   25    4      21             17.6           4.00          4.48        588             12.8          1.09           1.24           227             110          **0.0**       **21**
  T-23       29    52     11             8.7            2.52          2.55        554             8.9           1.34           1.35           166             95           4.0           199
  **T-25**   25    12     8              7.7            2.24          4.34        463             7.2           1.42           1.23           **146**         813          2.1           25
  T-26       26    11     9              6.8            5.94          1.14        488             8.4           0.81           1.18           185             42           0.9           457
  T-27       43    5      29             7.5            2.52          3.89        263             7.1           0.60           1.04           126             13           2.6           50
  **T-28**   41    12     15             11.1           **2.11**      2.64        **264**         15.3          1.22           1.11           **86**          375          8.4           **0**

*Shaded values indicate hormone axis abnormalities as defined in Table [2](#T2){ref-type="table"}. \#BE, number of self-reported blast exposures meeting ACRM criteria for mTBI during military career; ACTH, adrenocorticotropin; Cort, cortisol; LH, luteinizing hormone; FSH, follicle-stimulating hormone; tTest, total testosterone; PRL, prolactin; TSH, thyroid-stimulating hormone; fT-4, free thyroxine; IGF-I, insulin-like growth factor-I; GH, growth hormone; AVP, vasopressin; OT, oxytocin*.

In addition to the findings of anterior pituitary hormone abnormalities in six Veteran participants with mTBI, eight instances of anomalous posterior pituitary hormone levels were found in six Veterans in the mTBI group, one of whom, T-28, also had evidence of presumptive GHD and hypogonadism. The plasma oxytocin concentration was unmeasurably low in this individual (Table [3](#T3){ref-type="table"}). None of the Veterans in the DC group were found to have abnormal posterior pituitary hormone values.

Three additional participants from the mTBI group (T-10, T-14, and T-22) also were found to have circulating oxytocin concentrations below the reference sample's 5th percentile level. Two of these participants, T-10 and T-22, also met our criteria for arginine vasopressin (AVP) deficiency: plasma vasopressin concentration below the 5th percentile of the reference level in combination with urine specific gravity less than 1.003. In addition, plasma vasopressin concentrations in participants T-2 and T-12 were abnormally elevated above the 95th percentile of the reference group.

Demographics, deployment history, blast exposure, and medication use
--------------------------------------------------------------------

After completion of hormone measurement and identification of Veterans with apparent hypopituitarism, participants in the T group were divided into two subgroups, based on the presence or absence of hormone abnormalities, for comparison of demographic, deployment history, blast exposure, and medication use data with each other and with the DC group. The three groups of Veteran participants did not differ in age, education, or body mass index at the time of enrollment, and the two mTBI subgroups did not differ significantly from one another on any of the measures of deployment history or blast exposure (Table [4](#T4){ref-type="table"}).

###### 

**Mean ± SEM and (range) for demographic, deployment, and blast exposure data for each group of participants**.

                                                                 DC (*n* = 7)                       mTBI without PTHP(*n* = 15)                              mTBI with PTHP(*n* = 11)
  -------------------------------------------------------------- ---------------------------------- -------------------------------------------------------- ---------------------------------------------------------
  **A. DEMOGRAPHICS**                                                                                                                                        
  Age (years)                                                    31.1 ± 3.3 (23--47)                29.7 ± 1.8 (24--46)                                      28.8 ± 1.5 (25--41)
  Education (years)                                              14.0 ± 0.7 (12--17)                13.3 ± 0.4 (11--16)                                      13.6 ± 0.5 (12--16)
  Marital status                                                 3/7 Married, 4/7 single            7/15 Married, 4/15 single, 2/15 divorced, 2/15 unknown   7/11 Married, 1/11 single, 1/11 separated, 2/11 unknown
  Body mass index (BMI)                                          28.5 ± 2.1 (*n* = 5)^†^            27.9 ± 1.3 (*n* = 14)^†^                                 29.0 ± 1.3 (*n* = 10)^†^
  **B. DEPLOYMENT HISTORY**                                                                                                                                  
  Number of deployments                                          1.7 ± 0.4 (1--3)                   1.9 ± 0.2 (1--4)                                         2.1 ± 0.3 (1--3)
  Time between first and second deployments (months)             14.3 ± 7.0 (3.5--27.5) (*n* = 3)   15.9 ± 3.1 (4.0--39.5) (*n* = 10)                        15.4 ± 2.4 (7.5--30.0) (*n* = 8)
  Time between second and third deployments (months)             6.0 ± 1.0 (5.0--7.0) (*n* = 2)     8.0 ± 2.0 (6--12) (*n* = 3)                              7.6 ± 2.0 (3.0--12.5) (*n* = 4)
  Time between third and forth deployments (months)                                                 8.0 ± 0.0 (*n* = 1)                                      
  Total deployment time (months)                                 13.0 ± 1.8 (7--21)                 18.7 ± 2.2 (7--37)                                       18.2 ± 1.7 (11--27)
  **C. BLAST EXPOSURE**                                                                                                                                      
  Deployment blast exposures meeting ACRM criteria for mTBI      0                                  11.1 ± 3.3 (1--52)                                       14.6 ± 5.4 (4--66)
  Blast exposures meeting ACRM criteria during military career   0.3 ± 0.3 (0--2)                   24.5 ± 8.7 (1--102)                                      16.7 ± 5.2 (4--66)
  Blast exposures with LOC                                       0                                  1.3 ± 0.3 (0--4)                                         0.6 ± 0.2 (0--2)
  Lifetime events with LOC                                       0.1 ± 0.1 (0--1)                   3.1 ± 0.7 (0--11)                                        1.3 ± 0.4 (0--3)
  Time since last blast exposure (months)                                                           45.2 ± 4.2 (14--66)                                      47.4 ± 4.3 (20--67)

*The Veterans with blast mTBI (T group) were divided into two subgroups based upon the presence or absence of abnormal hormonal profiles suggesting PTHP. ^†^BMIs were not obtained for all participants*.

Concurrent medications
----------------------

Medications with potential neuroendocrine effects taken by mTBI subjects found to have indications of hypopituitarism were opiates (2/11), prazosin (2/11), selective serotonin reuptake inhibitors (SSRIs; 4/11), serotonin and norepinephrine reuptake inhibitors (SNRIs; 2/11), hypnotics (2/11), atypical antipsychotics (1/11), calcium channel blockers for migraine (1/11), benzodiazepines (1/11), and mirtazapine (1/11). Five subjects in this group were not taking any neuroactive medications. Medications with potential neuroendocrine effects taken by mTBI subjects found to have hormone levels within normal ranges were opiates (1/15), prazosin (4/15), SSRIs (3/15), SNRIs (2/15), mirtazapine (1/15), trazodone (1/15), benzodiazepines (1/15), and disulfiram (1/15). Nine subjects in this group were not taking any neuroactive medications. Medications with potential neuroendocrine effects taken by DC subjects were opiates (1/7), SSRIs (1/7), and SNRIs (1/7). Five subjects in this group were not taking any neuroactive medications.

Discussion
==========

Our findings in this preliminary study support the hypothesis that blast mTBI carries a risk of PTHP similar to that found in several previous studies of hypopituitarism in the general population after TBI from all causes. We have found that blood samples from 11 of 26, or 42% of Veterans of combat in Iraq or Afghanistan had abnormal circulating hormone concentrations consistent with PTHP. Five participants with blast mTBI exhibited evidence of anterior pituitary dysfunction, five additional subjects had anomalous posterior pituitary hormone levels, and the eleventh was found to have both anterior and posterior pituitary hormonal abnormalities. In contrast, none of the seven Veterans of deployment to Iraq and/or Afghanistan in the study who did not experience blast trauma -- the DC group -- were found to have evidence of pituitary dysfunction.

As Kokshoorn et al. ([@B53]) pointed out in their review of 14 investigations of PTHP conducted between 2000 and 2009, these early studies used a broad variety of screening criteria that were sometimes described in general terms rather than with specifically defined cutoffs. We attempted to use relatively conservative and explicitly defined criteria based on the distribution of specific hormone concentrations measured in a reference population. We did not employ provocative testing but used criteria based on measurement of both pituitary hormones and their target-organ hormones when possible, e.g., a combination of measurements of total testosterone, LH, FSH, and prolactin to screen for hypogonadism.

It should be cautioned that the determinations of basal hormone concentrations, such as those made in this study, are meant to be screening tools, and are not intended to be, nor should they be interpreted to be, diagnostic in the absence of clinical assessment. Measurement of basal circulating hormone concentrations is generally considered an appropriate screening tool for provisional identification of deficient thyroid function, hypogonadism, and prolactin and oxytocin deficiencies. Diagnosis of significant abnormalities of vasopressin secretion normally require confirmation by measures of plasma and/or urine osmolality, urine specific gravity (UGS), and/or the administration of a water deprivation test. Although provocative testing is generally considered necessary for diagnosis of sAI and GHD, measurement of basal cortisol and IGF-I concentrations remain valuable screening tools to identify individuals most likely to benefit from additional testing and clinical referral. Evaluation of clinical signs and symptoms are essential for definitive diagnoses in all cases.

Previous studies have found GHD to be the most prevalent chronic endocrine consequence of TBI, and it carries with it a potentially large range of symptoms. Provocative testing is considered to be a requisite for the reliable diagnosis of GHD because serum GH concentrations measured in the morning are not valid indicators of daily secretion or somatotroph function. GH secretion occurs predominantly during sleep, and morning levels are generally very low but punctuated unpredictably by short secretory bursts (Van Cauter et al., [@B102]). However, GH stimulates hepatic production of IGF-I that provides a useful index of somatotroph function. IGF-I concentrations have low diagnostic sensitivity for identifying GHD but are highly specific. The presence of normal IGF-I values cannot be used to exclude GDH because it is often diagnosed in individuals with normal or even elevated IGF-I levels. However, markedly low age-adjusted levels of IGF-I are strongly indicative of GHD (Juul et al., [@B46]; Hadjadj et al., [@B38]; Ho, [@B42]; Prodam et al., [@B74]; Tanriverdi et al., [@B91]; Zgaljardic et al., [@B106]). Circulating IGF-I concentrations decline markedly with increasing age, and this decline must be taken into account when interpreting them.

Studies using receiver operating characteristic (ROC) analysis to compare the diagnostic accuracy of IGF-I relative to diagnosis of GHD based on provocative testing of GH secretion have reported a diagnostic specificity of 100% with IGF-I SDS cutoffs of −1.3 (Corneli et al., [@B23]) or −1.7 (Maghnie et al., [@B59]).

The individuals classified here as having a high probability of GHD all had values less than −1.4 SDs below the age-adjusted means of the reference sample. The high specificity of IGF-I measurements at this level assures a very low likelihood of false positives in diagnosing GHD. However, in light of the low sensitivity of IGF-I concentrations in predicting GHD, it is probable that some Veteran participants with normal IGF-I levels may be growth hormone deficient.

The long-term sequelae of GHD in adults for health, quality of life (QoL), and morbidity are multifaceted and complex. Low GH secretion has been associated with behavioral symptoms and deficits in several cognitive domains (Popovic et al., [@B72]; Falleti et al., [@B30]; Pavlovic et al., [@B71]). GHD also has significant deleterious effects on body composition and cardiovascular function. Adult GHD is associated with lipidemia, reduced lean body mass, and increased adiposity. Even partial GHD in adult patients is associated with adverse lipid profiles and early atherosclerosis (Colao et al., [@B21],[@B22]; Colao, [@B20]). Impairment in QoL is also a prominent feature of adult GHD, especially in the areas of energy and vitality (McGauley, [@B64]; Kelly et al., [@B50]; Bushnik et al., [@B15]; Svensson et al., [@B89]; Bavisetty et al., [@B8]). Adult GHD is also associated with reductions in muscle volume and strength, decreased physical mobility, fatigue, sleep impairment, social isolation, depression, lowered metabolic rate, low sexual drive, and reduced aerobic capacity (Rosén et al., [@B79]; Mossberg et al., [@B68]).

Many of the symptoms of GHD can be successfully ameliorated or reversed by growth hormone replacement therapy. Five retrospective studies have shown that the risk of premature death from cardiovascular disease is elevated in patients with GHD (Svensson et al., [@B87]). The increased risk factors such as adverse lipid profiles, increased blood pressure, abnormal body composition, increased body weight, increased coagulability, and increased markers of inflammation have all been shown to improve with GH replacement (Svensson et al., [@B87], [@B89]; Götherström et al., [@B33]; Verhelst and Abs, [@B105]). GH replacement has been found to be effective in reversing cognitive impairments in several domains including simple motor speed, information processing speed, episodic memory, mental flexibility, verbal memory, and executive functioning in patients after TBI (High et al., [@B41]; Reimunde et al., [@B78]). GH replacement also normalizes muscle strength and increases bone mineral density (Götherström et al., [@B34], [@B35]), improves psychiatric functioning by ameliorating depression, intensity of interpersonal sensitivity, hostility, paranoid ideation, and anxiety (Maric et al., [@B60]), and improves QoL (Svensson et al., [@B88], [@B89]; Kreitschmann-Andermahr et al., [@B55]).

Three of the Veteran participants in the T group met our criteria for hypogonadism: a total testosterone concentration less than the 5th percentile of the reference sample together with an LH or FSH level below the 10th percentile reference level. In our very small sample, the occurrence of hypogonadism was found to be next highest in frequency to that of GHD, as was the case in several of the studies of PTHP after TBI from all causes in the general population (Bavisetty et al., [@B8]; Dusick et al., [@B28]; Krahulik et al., [@B54]; Park et al., [@B70]; Tanriverdi et al., [@B98]).

Hypogonadism has significant deleterious consequences in addition to its adverse effects on fertility, psychosexual function, and general well being. Testosterone deficiency in males is associated with decreased energy and motivation, muscle weakness, reduced lean body mass, and impaired exercise tolerance (Agha and Thompson, [@B4]). In addition, a recent large epidemiological study has shown that untreated hypogonadism is associated with premature mortality secondary to cardiovascular disease (Tomlinson et al., [@B100]).

One mTBI participant, T-4, was found to have a highly elevated concentration of prolactin, 2.5 times higher than the next highest concentration measured in the T group and more than four times higher than the highest value in the DC group. Hyperprolactinemia has been causally linked with hypogonadism, specifically by reducing LH and FSH secretion, blocking LH stimulation of testicular testosterone secretion, and producing oligospermia by reducing FSH levels, resulting in hypoactive sexual desire and erectile dysfunction.

Prolactin is the only anterior pituitary hormone that is under predominantly inhibitory control. Its secretion is suppressed by dopamine, and in the absence of this inhibition, prolactin is released at high levels. Hyperprolactinemia frequently results from the use of antipsychotic medications that act as antagonists at dopamine D2 receptors (Holt, [@B44]; Inder and Castle, [@B45]).

Participant T-4 had been taking quetiapine, an atypical antipsychotic with fast dissociation kinetics at the D2 receptor \[released from D2 within 12--24 h (Seeman, [@B84])\] that results only in low and transient prolactin secretion (Carboni et al., [@B18]). It has not generally been associated with hyperprolactinemia in clinical use (Haddad and Wieck, [@B37]; Byerly et al., [@B16]; Bushe et al., [@B14]) although a prevalence of 22% was found in one study (Montgomery et al., [@B67]). It is often referred to as a dopamine-sparing antipsychotic, and although it is much less potent in elevating prolactin levels than several other antipsychotics (e.g., haloperidol and risperidone), it may have prolactin-elevating effects in some individuals, perhaps including participant T-4.

One of the Veterans with mTBI was found to have a subnormal (less than 5th percentile) prolactin concentration. Hypoprolactinemia is rare in the general population, but it too has been associated with sexual dysfunction, primarily arteriogenic erectile dysfunction and premature ejaculation (Corona et al., [@B24]).

We found no evidence of dysfunction in the thyroid or adrenal axes as a result of blast mTBI. Previous studies of pituitary deficiencies after TBI from all causes have generally reported a lower prevalence of TSH and adrenocorticotropin (ACTH) deficiencies than of GH or gonadotropin deficits (Bavisetty et al., [@B8]; Blair, [@B12]; Krahulik et al., [@B54]). This pattern may be due in part to the location of pituitary corticotrophs and thyrotrophs in the gland's protected median wedge and their blood supply via both the long hypophysial portal vessels and the inferior hypophysial artery. GH-secreting somatotrophs, on the other hand, are anatomically more vulnerable to damage because of their location in the pituitary's exposed lateral wings and their primary dependence on vascular input from the portal system alone. Gonadotrophs are distributed throughout the anterior pituitary, and the cells in the lateral wings are relatively vulnerable.

In addition to the six participants with hormonal levels consistent with hypogonadism and/or GHD, six of the Veterans with mTBI (including one with anterior pituitary hormonal abnormalities) exhibited abnormal plasma vasopressin and/or oxytocin concentrations. Oxytocin concentrations below the 5th percentile value of the community control group were observed in four of the mTBI participants. Two of the four also exhibited indications of vasopressin deficiency as defined by vasopressin levels below the 5th percentile of the community reference group together with urine specific gravity less than 1.003. The occurrence of deficits of both vasopressin and oxytocin in two participants suggests the possibility of disruption of the pituitary stalk or hypothalamic damage in these individuals. In addition, elevated plasma vasopressin concentrations above the reference 95th percentile were measured in two subjects.

In several studies, elevated cerebrospinal fluid (CSF) or peripheral vasopressin concentrations have been associated with PTSD, depression, schizophrenia, and other psychiatric disorders, but a causal relationship has not been established (Purba et al., [@B75]; van Londen et al., [@B104]; Coccaro et al., [@B19]; Merali et al., [@B65]; de Kloet et al., [@B25]; Goekoop et al., [@B32]; Heinrichs et al., [@B40]). In contrast, there is evidence from both animal and human studies for the positive association of oxytocin levels with social bonding, attenuation of stress responses in socially relevant challenges, mediation of social support, and positive social interactions (Heinrichs et al., [@B40]; Campbell, [@B17]).

Our finding of a high frequency of abnormal peripheral hormone levels after blast mTBI in this preliminary study is consistent with the investigations cited above, in which the prevalence of pituitary dysfunction fell in the 30--60% range in 11 of 22 reports. However, in general, those studies focused exclusively on anterior pituitary dysfunction. Although few studies have investigated the prevalence of chronic posterior pituitary hormonal abnormalities after TBI, most (Agha et al., [@B2], [@B3]; Krahulik et al., [@B54]), but not all (Bondanelli et al., [@B13]), found significant evidence of damage in that lobe as well. In this study we found significant anterior pituitary dysfunction in 23.1% of Veterans with mTBI and abnormal posterior pituitary hormone levels in 23.1% of this group as well. In contrast, the prevalence of hypopituitarism in the general adult population ranges between 290 and 455 cases per million (Regal et al., [@B77]).

The only other ongoing study of hypopituitarism after blast mTBI of which we are aware recently reported preliminary results based on two retrospective chart reviews. Of 147 Marines with blast-related mTBI screened approximately 1 year or more after injury, 25% were found to have abnormal levels of one or more anterior pituitary hormones (Stokes and Gallagher, [@B86]).

The Veteran groups in this study are highly similar in demographic characteristics and share the common experience of deployment under highly stressful and dangerous conditions accentuated by extreme heat and the burden of heavy equipment even when not actively engaged in combat. Despite these commonalities, the experience of blast trauma and the combat situations in which these exposures occur have major long-term consequences well beyond those of deployment to Iraq or Afghanistan. The considerable overlap between the constellations of symptoms typical of chronic hypopituitarism and persistent post-concussive symptoms (PPCS), in addition to the similarities of both to PTSD, make accurate diagnosis of the etiology, progression, and identifiable differences between the conditions of critical importance for successful treatment, recovery, and rehabilitation (Masel, [@B63]).

The consequences of undiagnosed and untreated pituitary hormone deficiencies are manifold and significant and include diminished QoL, cognitive deficiencies, fatigue, sleep disturbance, sexual dysfunction, deleterious changes in metabolism and body composition, behavioral and psychiatric problems including anxiety, irritability, social isolation, depression, and increased cardiovascular mortality. PTHP, unlike PTSD and PPCS, is readily treatable if correctly diagnosed, and many of its symptoms can be reversed or ameliorated with appropriate hormone replacement therapy.

Several of the authors of previous studies of hypopituitarism after TBI have advocated routine endocrine evaluation after brain injury (Masel, [@B62]; Leal-Cerro et al., [@B56]; Schneider et al., [@B82]; Urban et al., [@B101]; Powner et al., [@B73]; Behan and Agha, [@B9]; Ho, [@B42]; Behan et al., [@B10]; Tanriverdi et al., [@B94], [@B98]; Blair, [@B12]; Krahulik et al., [@B54]; Park et al., [@B70]). A recent review of the literature (Guerrero and Alfonso, [@B36]) stated that because "many of the symptoms of hypopituitarism are similar to those of TBI, it is important to make clinicians caring for combat veterans aware of its occurrence... All patients who had a TBI of any severity, should undergo baseline hormonal evaluation."

To our knowledge, this is the first published study of basal hormonal evaluation of combat Veterans with blast mTBI, and our preliminary findings of PTHP in 42% of study participants supports the advisability of routine screening for hypopituitarism after brain injury in both military and civilian populations. Routine provocative testing for sAI and for GHD, the most frequently observed chronic endocrine disorder resulting from TBI, is neither economically nor practically viable. However, measurement of basal concentrations of a panel of pituitary and target-organ hormones similar to those performed here may provide valuable preliminary indications of those individuals most likely to benefit from further clinical evaluation. Similar preliminary screening for pituitary dysfunction after blast concussion shows promise for appropriately directing diagnostic and therapeutic decisions that otherwise may remain unconsidered and for markedly facilitating recovery and rehabilitation.
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